

Key Market Driver In Kesimpta Industry 2025: Increasing Multiple Sclerosis Prevalence On The Growth Of Market

The Business Research Company's Key Market Driver In Kesimpta Industry 2025: Increasing Multiple Sclerosis Prevalence On The Growth Of Market

LONDON, GREATER LONDON, UNITED KINGDOM, March 8, 2025

[/Einpresswire.com/](https://www.einpresswire.com/) -- Updated 2025

Market Reports Released: Trends,

Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



The Business
Research Company

Kesimpta Market Report 2025

How Has the Kesimpta Market Performed in Recent Years?

- The Kesimpta market has experienced notable growth, with an HCAGR of XX% in past years.

“

It will grow to \$XX million in 2029 at a compound annual growth rate (CAGR) of XX%.”

The Business Research Company

- The market is expected to expand from \$XX million in 2024 to \$XX million in 2025, driven by a CAGR of XX%.

- Several key factors have contributed to this growth, including:

- o Wider access to healthcare services
- o Advancements in biological therapies
- o Increasing prevalence of multiple sclerosis (MS)
- o Regulatory approvals for Kesimpta

- o Greater understanding of multiple sclerosis and treatment options

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20126&type=smp>

What Is the Future Growth Projection for the Kesimpta Market?

- The Kesimpta market is projected to witness an FCAGR of XX% in the coming years.
- By 2029, the market size is expected to reach \$XX million, growing at a CAGR of XX%.
- Several factors will drive this future growth:
 - o Strong support from healthcare providers
 - o Rising demand for subcutaneous injections

- o Increasing awareness of multiple sclerosis and available treatments
- o Higher prevalence of multiple sclerosis globally
- o Regulatory approvals for new indications of Kesimpta
- Emerging market trends include:
 - o Advancements in multiple sclerosis treatments
 - o Expansion into emerging markets
 - o Growing preference for self-administration therapies
 - o Regulatory approvals and product expansions
 - o A shift towards personalized medicine

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/kesimpta-global-market-report>

What Factors Are Driving the Kesimpta Market's Growth?

The increasing prevalence of multiple sclerosis (MS) is a primary driver of market expansion. MS is a chronic autoimmune disorder that affects the central nervous system, leading to nerve fiber damage and symptoms like muscle weakness, vision impairment, and cognitive decline. Kesimpta plays a crucial role in managing relapsing MS by targeting B-cells, reducing relapses, and slowing disease progression. Reports indicate a rising number of MS diagnoses, further fueling the demand for Kesimpta.

Who Are the Leading Players in the Kesimpta Market?

The Kesimpta market is primarily led by Novartis AG, a major pharmaceutical company contributing significantly to market growth through product innovations and industry-leading initiatives.

What Are the Emerging Trends in the Kesimpta Market?

A key trend in the market is the shift towards self-administered B-cell therapies for relapsing multiple sclerosis. This approach provides greater treatment convenience, reduces relapse rates, and improves patient adherence.

For instance, in April 2024, Novartis AG published six-year efficacy data for Kesimpta (ofatumumab), highlighting its benefits for newly diagnosed, treatment-naïve patients with relapsing MS.

How Is the Kesimpta Market Segmented?

The Kesimpta market is divided into several key segments:

1. By Indication:
 - o Treatment of Relapsing Multiple Sclerosis (RMS)
 - o Treatment of Clinically Isolated Syndrome (CIS)
 - o Treatment of Active Secondary Progressive Multiple Sclerosis (SPMS)
2. By Formulation:
 - o Injectable formulation
 - o Pre-filled syringes or autoinjectors

3. By Patient Demographics:

- o Pediatric patients
- o Adult patients
- o Geriatric patients

4. By Distribution Channel:

- o Direct sales
- o Wholesalers and distributors
- o Retail pharmacies
- o Online pharmacies

5. By End User:

- o Hospitals
- o Specialty pharmacies
- o Home healthcare providers
- o Neurology clinics

Which Regions Are Leading the Kesimpta Market?

- North America was the largest market for Kesimpta in 2024.
- Asia-Pacific is expected to be the fastest-growing region in the forecast period.
- The Kesimpta market spans multiple regions, including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

To Gain Further Insights, Browse More Similar Reports By [The Business Research Company](#).

Multiple Sclerosis Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report>

Anti-Inflammatory Therapeutics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report>

Autoinjectors Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/autoinjectors-global-market-report>

Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/791986687>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.